Donate

News

Categories
Sign up to our newsletter

News

New Agents Transform Treatment of NHL
published March 18, 2016
NEW AGENTS TRANSFORM THE TREATMENT OF NHLClick here to read more Advances for Non Hodgkin Lymphoma
Read more
Reduced Intensity Allogeneic Transplant effective for Follicular Lymphoma
published March 9, 2016
Reduced Intensity Salvage Allo-HCT Effective for Follicular LymphomaReduced intensity allogeneic hematopoietic
Read more
CAR T CELL Therapy is a new and exciting therapy
published February 4, 2016
 CAR T-cell therapy poised to shift hematologic malignancies treatment paradigmClick here for more inform
Read more
CLL is clinically recognised as a form of lymphoma and new therapies are changing lives
published February 1, 2016
New drug causes cancer to "melt away" in patients with advanced CLLIt worked in 79% of patients. Rea
Read more
Clinical Impact of Molecular Features for DLBC and FL
published January 26, 2016
http://www.bloodjournal.org/content/127/2/181?rss=1&sso-checked=true
Read more
Our Faces of Change
published December 17, 2015
Our Faces of Change – Thank you! Lymphoma Australia was founded in 2003 by a group of volunteers and became
Read more
New Treatment for Mantle Cell Lymphoma
published December 2, 2015
New Treatment for Mantle Cell Lymphoma Doctors at the Peter MacCallum Cancer Centre and the Royal Melbourne
Read more
Parliament 2 Opera 2015 kicked off our World Lymphoma Awareness month campaign
published October 26, 2015
Parliament 2Opera 2015 kicked off our World Lymphoma Awareness month campaign. This is the fifth year that P2
Read more
Australian First
published October 26, 2015
Australian First Italian Lymphoma and CLL patients were given the unprecedented opportunity chance to hear th
Read more
CLL and SLL patient meeting in Sydney
published October 6, 2015
The recent CLL /SLL patient education day in Sydney was a very informative and interactive event that aimed to
Read more
Thank you Nate Myles and Gold Coast Titans
published August 26, 2015
  Aquis Titans skipper Nate Myles had a special Sunday – leading the side to victory and promoting aware
Read more
Roadmap for Discovery and Translation in Lymphoma
published March 30, 2015
The Roadmap for Discovery and Translation in Lymphoma identifies key priority areas in both infrastructure and
Read more
Cart
Checkout - $0.00
  • 0
  • 1

Contact Lymphoma Australia Today!

Patient Support Hotline

General Enquiries

Please note: Lymphoma Australia staff are only able to reply to emails sent in English language.

For people living in Australia, we can offer a phone translation service. Have your nurse or English speaking relative call us to arrange this.

Newsletter Sign Up

Useful Definitions

  • Refractory: This means the lymphoma does not get better with treatment. The treatment didn’t work as hoped.
  • Relapsed: This means the lymphoma came back after being gone for a while after treatment.
  • 2nd line treatment: This is the second treatment you get if the first one didn’t work (refractory) or if the lymphoma comes back (relapse).
  • 3rd line treatment: This is the third treatment you get if the second one didn’t work or the lymphoma comes back again.
  • Approved: Available in Australia and listed by the Therapeutics Goods Administration (TGA).
  • Funded: Costs are covered for Australian citizens. This means if you have a Medicare card, you shouldn’t have to pay for the treatment.[WO7]

You need healthy T-cells to make CAR T-cells. For this reason, CAR T-cell therapy cannot be used if you have a T-cell lymphoma – yet.

For more information on CAR T-cells and T-cell lymphoma click here. 

Special Note: Although your T-cells are removed from your blood for CAR T-cell therapy, most of our T-cells live outside of our blood – in our lymph nodes, thymus, spleen and other organs.